The invention generally concerns compositions and methods for genetic vaccination with amyloid beta (A.beta.) protein. Such vaccines may provide effective treatment for neurodegenerative disease such as Alzheimer's disease. Vaccination methods are can be used to induce a Th2 type immune response directed to A.beta.. This immune response id shown to substantially reduce A.beta. concentration and A.beta. plaque size in an Alzheimer's model system.